Mylan launches first generic Xopenex "at risk" in US
This article was originally published in Scrip
Executive Summary
Mylan Laboratories's Dey subsidiary has launched levalbuterol inhalation solution 0.25% (1.25mg/0.5mL), the first generic version of Sepracor's short-acting beta-agonist Xopenex, "at risk" in the US as patent litigation with the innovator continues.